Skip to main content
MedPathMedPath Home
Clinical Trials/2023-506305-18-01
2023-506305-18-01
Completed
Phase 1

An open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of multiple doses of the gastric acid-reducing agent rabeprazole on the single dose pharmacokinetics of a 40 mg deucrictiban extended-release (XR) tablet.

Pharvaris Netherlands B.V.1 site in 1 country14 target enrollmentStarted: September 9, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Status
Completed
Sponsor
Pharvaris Netherlands B.V.
Enrollment
14
Locations
1
OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages
18 years to 64 years (18-64 Years)
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Pharvaris Netherlands B.V.
Sponsor Class
Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

Clinical Trials

Scientific

Pharvaris Netherlands B.V.

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
An open-label, single-sequence crossover drug-drug interaction study to evaluate the effect of multiple oral doses of itraconazole on the pharmacokinetics of PHA-022121 in healthy subjects
NL-OMON49496Pharvaris BV14
Completed
Not Applicable
An open-label, single-sequence cross-over drug-drug interaction study to evaluate the effect of single and multiple oral doses of PHA-022121 on the pharmacokinetics of selective CYP1A2, CYP2C19, and CYP3A4 substrates in healthy subjectsHereditary Angioedema10027664
NL-OMON49587Pharvaris Netherlands BV14
Unknown
Phase 3
An open-label, add-on, drug-drug interaction study to assess the effect of FYX-051 on the pharmacokinetics and safety of warfarin in Japanese healthy adult maleHealthy adult male
JPRN-jRCT2080221293SANWA KAGAKU KENKYUSHO CO.,LTD.12
Unknown
Phase 3
An open-label, add-on, drug-drug interaction study to assess the effect of FYX-051 on the pharmacokinetics and safety of warfarin in Japanese healthy adult male
jRCT2080221293SANWA KAGAKU KENKYUSHO CO.,LTD.12
Unknown
Phase 1
A clinical trial to check activity of certain enzymes in the body after taking a drug called AEB071
CTRI/2009/091/000582Novartis Healthcare Pvt. Ltd.18